JAN Stock Analysis: Janus Living | NYSE
REIT - Residential | NYSE, USA | Market Cap: 11.095m USD | 12M Return: 35.9% | US4710241096 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 78.0M
Warnings
Tailwinds
Seasonality 0.6 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Janus Living, Inc. (NYSE: JAN) is a Denver-based real estate investment trust (REIT) focused exclusively on the U.S. senior housing sector. The company is headquartered in Denver, Colorado, and positions itself as the only U.S. publicly traded REIT dedicated solely to senior housing properties. Its portfolio is operated entirely under RIDEA (REIT Investment Diversification and Empowerment Act) structures, which allow REITs to participate in both rental income and operating income through taxable REIT subsidiary (TRS) arrangements, rather than relying on traditional triple-net lease models.
As of December 31, 2025, Janus Livings initial portfolio consisted of 34 senior housing communities totaling 10,422 units, located primarily in major retirement markets across 10 U.S. states. Geographic concentration is significant, with units in Florida and Texas representing 69% of total units-a reflection of those states longstanding appeal as retirement destinations due to warm climates and favorable tax environments.
Under its RIDEA structure, the operators of Janus Livings communities generate revenue primarily through direct resident payments rather than governmental reimbursement programs such as Medicare or Medicaid. This arrangement, common in private-pay senior housing segments like independent living, assisted living, and memory care, provides the REIT with greater cash flow visibility compared to operators reliant on government payors. Janus Living is classified under the GICS Real Estate sector and the Multi-Family Residential REITs sub-industry.
- Senior housing demand rises with aging baby boomer population
- Geographic concentration in Florida and Texas limits regional diversification
- RIDEA structure avoids Medicare/Medicaid reimbursement risk
| Net Income: -20.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.03 > 1.0 |
| NWC/Revenue: -19.53% < 20% (prev -16.16%; Δ -3.37% < -1%) |
| CFO/TA 0.03 > 3% & CFO 154.6m > Net Income -20.1m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 0.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (302.2m) vs 12m ago 67.06% < -2% |
| Gross Margin: 13.70% > 18% (prev 100.0%; Δ -86.30% > 0.5%) |
| Asset Turnover: 23.07% > 50% (prev 16.16%; Δ 6.91% > 0%) |
| Interest Coverage Ratio: -12.87 > 6 (EBIT TTM -30.9m / Interest Expense TTM 2.40m) |
| A: -0.04 (Total Current Assets 521.6m - Total Current Liabilities 718.4m) / Total Assets 5.22b |
| B: -0.02 (Retained Earnings -102.0m / Total Assets 5.22b) |
| C: -0.01 (EBIT TTM -30.9m / Avg Total Assets 4.37b) |
| D: 2.84 (Book Value of Equity 3.11b / Total Liabilities 1.09b) |
| Altman-Z'' = 2.63 = A |
| DSRI: 2.31 (Receivables 95.6m/23.3m, Revenue 1.01b/568.5m) |
| GMI: 7.30 (GM 100.0% / 13.70%) |
| AQI: 1.70 (AQ_t 0.48 / AQ_t-1 0.28) |
| SGI: 1.77 (Revenue 1.01b / 568.5m) |
| TATA: -0.03 (NI -20.1m - CFO 154.6m) / TA 5.22b) |
| Beneish M = 4.73 (Cap -4..+1) = D |
As of November 14, 2026, the stock is trading at USD 31.82 with a total of 2,228,854 shares traded. Over the past week, the price has changed by -0.38%, over one month by +10.64%, over three months by +6.98% and over the past year by +35.89%.
Current recommended Stop Loss: 30.40 (which is 4.5% or 1.3 ATR below the current price).
Janus Living has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy JAN.
- StrongBuy: 7
- Buy: 6
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.5 | 8.5% |
P/S = 13.1954
P/B = 2.7943
Revenue TTM = 1.01b USD
EBIT TTM = -30.9m USD
EBITDA TTM = 339.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 10.8b USD (11.1b + (null Debt) - CCE 338.1m)
Interest Coverage Ratio = -12.87 (Ebit TTM -30.9m / Interest Expense TTM 2.40m)
EV/FCF = 264.3x (Enterprise Value 10.8b / FCF TTM 40.7m)
FCF Yield = 0.38% (FCF TTM 40.7m / Enterprise Value 10.8b)
FCF Margin = 4.04% (FCF TTM 40.7m / Revenue TTM 1.01b)
Net Margin = -1.99% (Net Income TTM -20.1m / Revenue TTM 1.01b)
Gross Margin = 13.70% ((Revenue TTM 1.01b - Cost of Revenue TTM 869.9m) / Revenue TTM)
Gross Margin QoQ = -30.74% (prev -25.54%)
Tobins Q-Ratio = 2.06 (Enterprise Value 10.8b / Total Assets 5.22b)
Interest Expense / Debt = unknown (Interest Expense 2.40m / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -24.4m (EBIT -30.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.73 (Total Current Assets 521.6m / Total Current Liabilities 718.4m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 339.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM 40.7m)
Total Stockholder Equity = 2.45b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.46% (Net Income -20.1m / Total Assets 5.22b)
RoE = -0.82% (Net Income TTM -20.1m / Total Stockholder Equity 2.45b)
RoCE = -0.69% (EBIT -30.9m / Capital Employed (Total Assets 5.22b - Current Liab 718.4m))
RoIC = -0.55% (negative operating profit) (NOPAT -24.4m / Invested Capital 4.45b)
WACC = 3.60% (E(11.1b)/V(11.1b) * Re(3.60%) + (debt-free company))
Discount Rate = 3.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.26 | Cagr: 50.76%
[DCF] Terminal Value 73.10% ; FCFF base≈49.8m ; Y1≈43.7m ; Y5≈35.3m
[DCF] Fair Price = 2.14 (EV 566.6m - Net Debt 0.0 = Equity 566.6m / Shares 264.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.05 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.11 | Chg30d=-39.82% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+63.5%
EPS next Year (2027-12-31): EPS=0.21 | Chg30d=+9.63% | Revisions=+0% | GrowthEPS=+88.3% | GrowthRev=+29.3%
[Analyst] Revisions Ratio: +0% (up=1, down=1)